QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

CADL

QT77Candel Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
8.31
+0.32+4.00%
OverviewShort InterestFilings
CADLQT77Candel Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
8.31+4.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own11.44%
Shs Outstand73.27M
Perf Week1.84%
Market Cap438.66MForward P/E-EPS next Y-0.67Insider Trans0.75%Shs Float-Perf Month8.49%
Enterprise Value245.62MPEG0.19EPS next Q-Inst Own-Short Float-Perf Quarter69.25%
Income-47901460.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y44.77%
Sales-P/B3.61EPS next Y28.85%ROA-26.95%Short Interest-Perf YTD47.08%
Book/sh1.88P/C-EPS next 5Y-ROE-60.42%52W High9.57 -13.17%Perf Year68.22%
Cash/sh2.66P/FCF-EPS past 3/5Y-ROIC-28.89%52W Low4.35 91.03%Perf 3Y-
Dividend Est.-EV/EBITDA-4.88Sales past 3/5Y-Gross Margin0.00%Volatility4.19% 4.48%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)0.58Perf 10Y-
Dividend Ex-Date-Quick Ratio28.05Sales Y/Y TTM-Profit Margin0.00%RSI (14)52.88Recom2.10
Dividend Gr. 3/5Y-Current Ratio28.05EPS Q/Q-SMA20-0.41%Beta2.05Target Price15.00
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5010.50%Rel Volume3.83Prev Close7.99
Employees38LT Debt/Eq0.02Earnings-SMA20041.04%Avg Volume2.14MPrice8.31
IPO DateJul 27, 2021Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA3.84Volume8,187,419Change4.00%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-27-25InitiatedStephensOverweight$15
Sep-03-25DowngradeB of A SecuritiesBuy → Neutral
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other181414
Research and Development301925
Other Operating Expense00-1
Operating Income-48-33-38
Interest Expense223
Unusual Expense
———
Non-Operating Income (Expense)-1220-3
Net Income Before Taxes-38-55-38
Income Taxes
000
Consolidated Net Income-38-55-38
Net Income From Continuing Operations-38-55-38
Net Income-38-55-38
EPS (Recurring)-0.72-1.74-1.31
EPS (Basic, Before Extraordinaries)-0.72-1.74-1.31
EPS (Diluted)-0.72-1.74-1.31
EBITDA-35-52-34
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding533229
Market Capitalization299——
Operating Lease Expense
———
Insider Trading Volume
$9.09$8.35$7.61$6.87$6.13● Close Price0.00M0.75M1.50M2.25M3.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Manning Paul BDirectorFeb 23 '26Buy5.45550,4582,999,9962,763,527Feb 26 12:00 AM
Nichols William GarrettChief Medical OfficerJul 28 '25Option Exercise1.291,8742,41853,430Jul 30 12:00 AM
Nichols William GarrettChief Medical OfficerJul 28 '25Sale6.989376,54052,493Jul 30 12:00 AM
Nichols William GarrettChief Medical OfficerJun 30 '25Option Exercise1.291,5622,01453,274Jul 02 12:00 AM
Nichols William GarrettChief Medical OfficerJun 30 '25Sale5.047813,93652,493Jul 02 12:00 AM
Tak Paul PeterChief Executive OfficerMar 19 '25Sale9.004003,601225,740Mar 20 12:00 AM
Nichols William GarrettChief Medical OfficerMar 18 '25Option Exercise1.9036,97870,254195,416Mar 20 12:00 AM
Nichols William GarrettChief Medical OfficerMar 18 '25Sale8.7645,316396,99552,493Mar 20 12:00 AM
Barone FrancescaChief Scientific OfficerMar 18 '25Option Exercise1.5536,00055,800128,673Mar 20 12:00 AM
Barone FrancescaChief Scientific OfficerMar 18 '25Sale8.7632,146281,67396,527Mar 20 12:00 AM
Tak Paul PeterChief Executive OfficerMar 18 '25Sale8.7725,772226,023226,140Mar 20 12:00 AM
Tyagarajan SeshuChief Technology OfficerMar 17 '25Option Exercise1.2940,00051,600116,790Mar 20 12:00 AM
Tyagarajan SeshuChief Technology OfficerMar 17 '25Sale8.8231,278275,94785,512Mar 19 12:00 AM
Schoch CharlesSee RemarksMar 17 '25Sale8.835,00044,16938,038Mar 19 12:00 AM
Barone FrancescaChief Scientific OfficerJan 15 '25Sale7.2213,53497,783110,673Jan 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR